Abbott Laboratories (ABT) Common Equity (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Common Equity data on file, last reported at $52.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 20730.43% year-over-year to $52.7 billion; the trailing twelve-month figure through Mar 2026 stood at $52.7 billion (up 20730.43% YoY), and the FY2025 full-year result was $52.8 billion, up 22166.24% from the prior year.
• Common Equity held at $52.7 billion in Q1 2026, from $52.8 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $52.8 billion in Q4 2025 to a low of -$8.7 billion in Q2 2022.
• A 5-year average of $15.3 billion and a median of $237.0 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 111.27% in 2024 and surged 213700.0% in 2025, its largest moves.
• Tracing ABT's Common Equity over 5 years: stood at $219.0 million in 2022, then soared by 11255.71% to $24.9 billion in 2023, then sank by 99.05% to $237.0 million in 2024, then soared by 22166.24% to $52.8 billion in 2025, then slipped by 0.13% to $52.7 billion in 2026.
• Business Quant data shows ABT's Common Equity at $52.7 billion in Q1 2026, $52.8 billion in Q4 2025, and $51.3 billion in Q3 2025.